Spero Therapeutics, Inc. (SPRO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0500 |
| Open | 1.0300 |
| Bid | 0.9400 x 1400 |
| Ask | 0.9800 x 1200 |
| Day's Range | 0.9400 - 1.1400 |
| 52 Week Range | 0.8550 - 19.8700 |
| Volume | |
| Avg. Volume | 753,998 |
| Market Cap | 30.384M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6670 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.60 |
- Skift
History of Short-Term Rentals Filled With Arrogance and Missed Opportunities
Looking back at the history of short-term rentals coming online starting in the mid-1990s, it’s easy to see how arrogant thinking and missed opportunities left their mark, and swayed the sector’s trajectory. That’s an easy takeaway from Skift’s recently published three-part Definitive Oral History of Short-Term Rentals because this theme of opportunities seized and lost […]
- Zacks
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206’s Phase 1 Data Support Further Development in Complicated Urinary Tract Infection, Hospital-acquired and Ventilator-associated Bacterial Pneumonia, and Bloodstream Infections Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., May
